The purpose of the study is to understand how using this cream over a period of six months might affect the bone mineral density of patients with bullous pemphigoid. Bone mineral density is a measure of the strength of bones, and it is important for overall bone health. The study will involve regular check-ups to monitor changes in bone mineral density, particularly in the spine and hip areas, as well as other health indicators like calcium and vitamin D levels in the blood.

Participants in the study will apply the clobetasol propionate cream to their skin as directed and will have their bone mineral density measured at the start of the study, after three months, and at the end of the six-month treatment period. The study will also look at the frequency of any bone fractures and how these might relate to the use of the cream. This research aims to provide valuable insights into the safety and effects of long-term use of topical corticosteroids in patients with bullous pemphigoid.

The purpose of this research is to determine if dupilumab is more effective than placebo in helping patients achieve sustained improvement of their condition while being able to stop using oral corticosteroids. The study will last for 52 weeks, during which patients will receive either dupilumab or a matching placebo through regular injections. Throughout the study, doctors will monitor the healing of skin blisters, reduction in itching, and overall improvement in the condition.

During the study, researchers will track various aspects of the disease, including changes in skin symptoms, intensity of itching, quality of life, and the presence of specific antibodies in the blood. They will also monitor the safety of the treatment by recording any side effects that may occur. The total amount of corticosteroids needed during treatment will be measured, as well as how long patients can maintain improvement without requiring oral corticosteroids.

Participants in the study will receive either the new treatment or a placebo, which looks like the treatment but does not contain any active medicine. The study will last for about 36 weeks, during which time participants will be monitored to see how well the treatment works and to check for any side effects. The study will also look at how the treatment affects the need for other medications, like oral corticosteroids, which are often used to manage bullous pemphigoid.

Throughout the study, participants will have regular check-ups to assess their skin condition and overall health. The goal is to determine if efgartigimod PH20 SC can help control the symptoms of bullous pemphigoid and reduce the need for other treatments. This research could lead to new options for managing this challenging skin condition.

Participants in the study will receive the treatment over a period of time, and researchers will monitor them to see how their bodies respond. The study will look at how often and how severe any side effects are, as well as how many participants stop the treatment due to safety concerns. The study will also assess how well the treatment works in managing the symptoms of Bullous Pemphigoid over time.

In addition to the main treatment, some participants may receive a substance called placebo, which looks like the treatment but does not contain the active ingredient. This helps researchers compare the effects of the actual treatment with no treatment. The study aims to provide valuable information about the potential benefits and risks of using efgartigimod PH20 SC for people with Bullous Pemphigoid.